Eli Lilly

LLY · Healthcare · Healthcare

Mentions

Podcasts

Episodes

Podcast consensus

Points of consensus

▶Eli Lilly has an oral GLP-1 drug for obesity in its pipeline that is currently undergoing the regulatory approval process and is not yet approved.Apr 2026

▶The company's injectable drug Zepbound is considered highly effective for weight loss and has been found to be cost-effective by the Institute for Clinical and Economic Review (ICER).Apr–May 2026

▶Eli Lilly is developing a one-time PCSK9 gene-editing therapy intended to permanently lower a patient's LDL cholesterol for life.Apr–May 2026

▶The company's Alzheimer's prevention study was the fastest-enrolling trial for the disease in history, having screened over 80,000 people using a decentralized model.May 2026

Points of debate

▶Regarding the oral obesity pill's efficacy, it is positioned as an effective maintenance treatment, yet clinical trial data shows patients who previously took Zepbound or Wegovy regained an average of 11 pounds and 2 pounds, respectively, after one year.Apr–May 2026

▶On insulin affordability, Eli Lilly offers a lower-priced authorized generic, but this was initially not covered by insurers and the higher-priced branded version still constitutes half its insulin volume due to the PBM rebate system.May 2026

▶The company's current anti-amyloid medicines for Alzheimer's can slow cognitive decline by approximately 30% in late-stage patients, which contrasts with speculative predictions of forthcoming data showing 'dramatic protective effects' when the medicine is administered early.Apr 2026

▶While Eli Lilly's drug development time is significantly faster than the industry average (under 7 years vs. 10), about half of this time is spent waiting to enroll patients in clinical trials, indicating a major operational bottleneck despite the overall efficiency.Apr 2026

Key themes

▶Dominance in Metabolic Disease

Eli Lilly has established a commanding position in the metabolic disease space, primarily through its GLP-1 franchise. Its drug Zepbound is noted for efficacy that rivals competitors and is considered highly cost-effective, while an oral GLP-1 successor is advancing through the regulatory pipeline, expected to serve as a maintenance therapy.

The company's strategy appears focused on creating a lifecycle of treatments, moving patients from highly effective injectables to convenient oral maintenance drugs, potentially locking in market share for the long term.

▶Pioneering Next-Generation TherapeuticsApr–May 2026

Beyond its current blockbusters, Eli Lilly is investing heavily in advanced therapeutic platforms. This includes a one-time gene-editing therapy targeting PCSK9 to permanently lower LDL cholesterol and a new approach to treating blood cancer acquired via the purchase of Colonia Therapeutics.

This focus on potentially curative, one-time treatments like gene editing signals a strategic shift away from chronic-care revenue models, which could fundamentally alter long-term valuation and risk profiles for the company.

▶Advancing the Frontier of NeuroscienceApr–May 2026

Eli Lilly is a key player in the challenging field of Alzheimer's disease. Its current anti-amyloid medicine offers a modest 30% slowing of cognitive decline in late-stage patients, but the company is running a historically fast-enrolling prevention study with expectations for data showing more dramatic protective effects.

Success in the Alzheimer's prevention trial would represent a paradigm shift from disease management to prevention, opening up a massive new market and cementing Lilly's status as a leader in neurological innovation.

▶Navigating and Reshaping US Healthcare EconomicsMay 2026

The company's experience with insulin pricing highlights the complexities of the PBM rebate system, where high list prices belie low net revenues. In response, Eli Lilly has introduced lower-priced generics and is experimenting with new business models like Lilly Direct, which sells directly to consumers.

Eli Lilly's direct-to-consumer push with Lilly Direct is a strategic attempt to bypass traditional intermediaries, which could disrupt the pharmaceutical distribution model and give the company greater control over pricing and patient relationships.

Source episodes

Sentiment over time

Apr 2026

10 bullish, 3 neutral(13 claims)

Viking Therapeutics reported positive data for an early-stage obesity drug candi...

May 2026

4 bullish, 1 bearish(5 claims)

Eli Lilly is developing a one-time PCSK9 gene-editing therapy intended to perman...

Changes over time

Historical Context

Due to the PBM rebate system, the list price for Eli Lilly's insulin rose to as high as $275, while the company's net revenue was only $30 to $40 per prescription.

Recent Past

Eli Lilly introduced a lower-priced authorized generic insulin. In its first year, it had poor insurance coverage but now accounts for about half of the company's total insulin volume.

Present

The company's valuation crossed the $1 trillion threshold, a first for a healthcare company. Its Alzheimer's prevention study became the fastest-enrolling in history, and its obesity drug Zepbound was deemed highly cost-effective by ICER.

Later This Year (Speculative)

Alex Karnal predicts Eli Lilly will release data showing its anti-amyloid medicine has 'dramatic protective effects' against Alzheimer's when used as a preventative measure.

Q1 2026 (Speculative)

Adam Feuerstein predicts the company's oral GLP-1 drug will likely receive FDA approval, possibly in March 2026.

Suggested prompts

How will the market dynamics for obesity treatments change with the potential approval of Eli Lilly's oral GLP-1, and how will its efficacy as a maintenance drug affect its adoption versus injectables? &nearr;What are the long-term commercial implications of Eli Lilly's investment in one-time gene-editing therapies like the PCSK9 treatment, compared to its chronic-use blockbuster drugs? &nearr;Given the mixed results of the oral obesity pill in maintenance trials (e.g., weight regain), what are the key risks to its projected market uptake and pricing strategy? &nearr;How does Eli Lilly's faster-than-average clinical development timeline (under 7 years vs. industry's 10) contribute to its competitive advantage, and can this pace be sustained across its diverse pipeline? &nearr;

Key concepts

GLP-1 Drugs (Zepbound & Oral Pill) 6 ep Alzheimer's Disease Treatment 2 ep Obesity Market 2 ep Corporate Strategy (M&A, Lilly Direct) 2 ep Valuation / Market Cap 2 ep Gene Editing / PCSK9 Therapy 1 ep Drug Pricing & PBMs 1 ep Clinical Trial Efficiency 1 ep Insulin 1 ep Cancer Treatment 1 ep

Notable quotes

“one of the highlights of this year was Eli Lilly crossing the $1 trillion market value threshold. you know, they are the first healthcare company to achieve a $1 trillion valuation.”

Adam Feuerstein · The Year in Biotech and What’s Ahead for 2026

“We've got amazing GLP-1 medicines that I started with that from clear data out of Eli Lilly show a 94% reduction in your risk of moving from being pre-diabetic to diabetic.”

Alex Karnal · Designing the Modern Health Stack | Alex Karnal

“today we've got some amazing medicines that are both Biogen and Eli Lilly that if you are late in the disease progression of Alzheimer's, you can start to slow the decline. We can slow that decline by about 30%.”

Alex Karnal · Designing the Modern Health Stack | Alex Karnal

“Eli Lilly is upending the traditional model by selling directly to their consumers over the internet with Lilly Direct, rather than through the traditional middlemen.”

Stripe Host · Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Report last updated: May 4, 2026

Get started free

Back to Entities Intelligence Report